{"description":"Documents matching 'marijuana rescheduling'","count":106,"total_pages":6,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=marijuana+rescheduling&format=json&page=2","results":[{"title":"Schedules of Controlled Substances: Rescheduling of Marijuana","type":"Proposed Rule","abstract":"This is notice that the Drug Enforcement Administration (\"DEA\") will hold a hearing with respect to the proposed rescheduling of marijuana into schedule III of the Controlled Substances Act beginning June 29, 2026. The proposed rescheduling of marijuana was initially proposed in a Notice of Proposed Rulemaking published in the Federal Register on May 21, 2024. In accordance with Executive Order 14370, DEA is completing this process in the most expeditious manner in accordance with Federal law.","document_number":"2026-08177","html_url":"https://www.federalregister.gov/documents/2026/04/28/2026-08177/schedules-of-controlled-substances-rescheduling-of-marijuana","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-28/pdf/2026-08177.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08177.pdf?1777293907","publication_date":"2026-04-28","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"ACTION: \n Notice of hearing on proposed rulemaking. \n \n \n SUMMARY: \n \n This is notice that the Drug Enforcement Administration (“DEA”) will hold a hearing with respect to the proposed <span class=\"match\">rescheduling</span> of <span class=\"match\">marijuana</span> into schedule III of the Controlled Substances Act beginning June 29, 2026. The proposed <span class=\"match\">rescheduling</span> of <span class=\"match\">marijuana</span> was initially proposed in a Notice of Proposed Rulemaking published in the \n Federal Register \n on May 21, 2024. In accordance with Executive Order 14370, DEA is completing this process in the most expeditious manner in accordance"},{"title":"Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal","type":"Proposed Rule","abstract":"The Department of Justice published a notice of proposed rulemaking in the Federal Register on May 21, 2024, which proposed to transfer marijuana from schedule I of the Controlled Substances Act to schedule III. The Drug Enforcement Administration (\"DEA\") published a notice of hearing on the proposed rule in the Federal Register on August 29, 2024. Upon further review, DEA is withdrawing the notice of hearing and terminating the pending hearing proceedings. As directed by Executive Order 14370, DEA has determined that the most expeditious manner of completing the rulemaking process in accordance with Federal law is to terminate the pending hearing proceedings and initiate new hearing proceedings. DEA is publishing a new notice of hearing elsewhere in this issue of the Federal Register.","document_number":"2026-08178","html_url":"https://www.federalregister.gov/documents/2026/04/28/2026-08178/schedules-of-controlled-substances-rescheduling-of-marijuana-withdrawal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-28/pdf/2026-08178.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08178.pdf?1777293907","publication_date":"2026-04-28","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"notice of proposed rulemaking (“NPRM”) in the \n Federal Register \n , \n which proposed to transfer <span class=\"match\">marijuana</span> from schedule I of the Controlled Substances Act to schedule III pursuant to the procedures defined in 21 U.S.C. 811(a).\n 1 \n \n Interested persons were invited to participate in the rulemaking effort by submitting written comments on the proposal or by requesting a hearing.\n 2 \n \n \n \n \n 1 \n  \n Schedules of Controlled Substances: <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span>, \n 89 FR 44597 (May 21, 2024).\n \n \n \n \n 2 \n  \n Id. \n at 44598-99.\n \n \n \n In response to the"},{"title":"Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements","type":"Rule","abstract":"With the issuance of this final rule, which constitutes a final order, the Acting Attorney General of the U.S. Department of Justice places drug products containing marijuana that have been approved by the Food and Drug Administration (FDA) in schedule III of the Controlled Substances Act (\"CSA\"). This action is required to satisfy the responsibility of the Administrator under the CSA to place a drug in the schedule he deems most appropriate to carry out United States obligations under the Single Convention on Narcotic Drugs, 1961. In general, this final rule applies to marijuana as defined in the CSA, marijuana extracts, and delta-9-tetrahydrocannabinol and other compounds derived from the marijuana plant (other than the mature stalks and seeds) that falls outside the definition of hemp, to the extent that any of these are included in an FDA-approved drug product or are subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes (\"state medical marijuana license\"). Also consistent therewith, this final rule adds such drugs to the list of substances that may only be imported or exported pursuant to a permit. This final rule also establishes an expedited registration process under 21 CFR part 1301 for entities holding state medical marijuana licenses, enabling such entities to engage in the manufacture, distribution, and/or dispensing of marijuana for medical purposes under federal law consistent with the requirements of the Single Convention.","document_number":"2026-08176","html_url":"https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-28/pdf/2026-08176.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08176.pdf?1777293907","publication_date":"2026-04-28","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"medical <span class=\"match\">marijuana</span> licenses from the requirement to monopolize the wholesale trade in <span class=\"match\">marijuana</span>. \n \n This final rule <span class=\"match\">rescheduling</span> <span class=\"match\">marijuana</span> contained in FDA-approved products or subject to a state medical <span class=\"match\">marijuana</span> license applies to <span class=\"match\">marijuana</span> as listed in 21 CFR 1308.11(d)(23), as well as <span class=\"match\">marijuana</span> extracts as defined in 21 CFR 1308.11(d)(58) because they meet the statutory definition of <span class=\"match\">marijuana</span> and, prior to 2017, were included in 21 CFR 1308.11(d)(23).\n 38 \n \n In addition, this final \n \n rule applies to Δ9-THC derived from the <span class=\"match\">marijuana</span> plant"},{"title":"Schedules of Controlled Substances: Rescheduling of Marijuana","type":"Proposed Rule","abstract":"This is notice that the Drug Enforcement Administration will hold a hearing with respect to the proposed rescheduling of marijuana into schedule III of the Controlled Substances Act. The proposed rescheduling of marijuana was initially proposed in a Notice of Proposed Rulemaking published in the Federal Register on May 21, 2024.","document_number":"2024-19370","html_url":"https://www.federalregister.gov/documents/2024/08/29/2024-19370/schedules-of-controlled-substances-rescheduling-of-marijuana","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-08-29/pdf/2024-19370.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-19370.pdf?1724705113","publication_date":"2024-08-29","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Substances: <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span>, \n 89 FR 44597 (May 21, 2024).\n \n \n The NPRM stated that if the transfer to schedule III is finalized, the regulatory controls applicable to schedule III controlled substances would apply, as appropriate, along with existing <span class=\"match\">marijuana</span>-specific requirements and any additional controls that might be implemented, including those that might be implemented to meet U.S. treaty obligations. If <span class=\"match\">marijuana</span> is transferred into schedule III, the manufacture, distribution, dispensing, and possession of <span class=\"match\">marijuana</span> would remain"},{"title":"Increasing Medical Marijuana and Cannabidiol Research","type":"Presidential Document","abstract":null,"document_number":"2025-23846","html_url":"https://www.federalregister.gov/documents/2025/12/23/2025-23846/increasing-medical-marijuana-and-cannabidiol-research","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23846.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-23846.pdf?1766420110","publication_date":"2025-12-23","agencies":[{"raw_name":"EXECUTIVE OFFICE OF THE PRESIDENT","name":"Executive Office of the President","id":538,"url":"https://www.federalregister.gov/agencies/executive-office-of-the-president","json_url":"https://www.federalregister.gov/api/v1/agencies/538","parent_id":null,"slug":"executive-office-of-the-president"}],"excerpts":"concurred with the FDA's recommendation that <span class=\"match\">marijuana</span> be <span class=\"match\">rescheduled</span> from Schedule I to Schedule III of the CSA. In May 2024, the Department of Justice issued a proposed rule to <span class=\"match\">reschedule</span> <span class=\"match\">marijuana</span> to Schedule III. The proposed rule received nearly 43,000 public comments and is currently awaiting an administrative law hearing. \n \n The Federal Government's long delay in recognizing the medical use of <span class=\"match\">marijuana</span> does not serve the Americans who report health benefits from the medical use of <span class=\"match\">marijuana</span> to ease chronic pain and other various medically"},{"title":"Schedules of Controlled Substances: Rescheduling of Marijuana","type":"Proposed Rule","abstract":"The Department of Justice (\"DOJ\") proposes to transfer marijuana from schedule I of the Controlled Substances Act (\"CSA\") to schedule III of the CSA, consistent with the view of the Department of Health and Human Services (\"HHS\") that marijuana has a currently accepted medical use as well as HHS's views about marijuana's abuse potential and level of physical or psychological dependence. The CSA requires that such actions be made through formal rulemaking on the record after opportunity for a hearing. If the transfer to schedule III is finalized, the regulatory controls applicable to schedule III controlled substances would apply, as appropriate, along with existing marijuana-specific requirements and any additional controls that might be implemented, including those that might be implemented to meet U.S. treaty obligations. If marijuana is transferred into schedule III, the manufacture, distribution, dispensing, and possession of marijuana would remain subject to the applicable criminal prohibitions of the CSA. Any drugs containing a substance within the CSA's definition of \"marijuana\" would also remain subject to the applicable prohibitions in the Federal Food, Drug, and Cosmetic Act (\"FDCA\"). DOJ is soliciting comments on this proposal.","document_number":"2024-11137","html_url":"https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-05-21/pdf/2024-11137.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-11137.pdf?1715958912","publication_date":"2024-05-21","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"802(16)(A), 812(c). As used in this NPRM, “<span class=\"match\">marijuana</span>” means the term defined at 21 U.S.C. 802(16).\n \n \n \n DEA and HHS last examined the issue of whether to <span class=\"match\">reschedule</span> <span class=\"match\">marijuana</span> eight years ago, in 2016, when DEA denied two petitions to <span class=\"match\">reschedule</span> <span class=\"match\">marijuana</span>.\n 5 \n \n At the time, HHS concurred that <span class=\"match\">marijuana</span> should remain a schedule I drug because it met the three criteria for placement in schedule I. 81 FR 53706-07. In accordance with the requirements for placement in schedule I, HHS found that: (1) <span class=\"match\">marijuana</span> had a high potential for abuse; (2) it did"},{"title":"Decision and Order: Medpharm Research, LLC","type":"Notice","abstract":null,"document_number":"2026-20553","html_url":"https://www.federalregister.gov/documents/2026/10/07/2026-20553/decision-and-order-medpharm-research-llc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-07/pdf/2026-20553.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20553.pdf?1791290716","publication_date":"2026-10-07","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"(e), (f)(1). \n II. Applicable Law \n \n <span class=\"match\">Marijuana</span>, as defined in the CSA, as well as <span class=\"match\">marijuana</span> extract and tetrahydrocannabinols \n 3 \n \n (hereinafter collectively referred to as <span class=\"match\">marijuana</span>), are Schedule I controlled substances, unless they are in a U.S. Food and Drug Administration approved product or subject to a state medical <span class=\"match\">marijuana</span> license under 21 CFR 1308.13(g) as Schedule III controlled substances. 21 U.S.C. 812(c), Schedule I(c)(10); 21 CFR 1308.11(d)(23), (31), (58); RFAAX 1, at 1.\n \n \n \n 3 \n  <span class=\"match\">Marijuana</span> extract and tetrahydrocannabinols are"},{"title":"JT Medical, LLC; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-19842","html_url":"https://www.federalregister.gov/documents/2026/09/29/2026-19842/jt-medical-llc-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-29/pdf/2026-19842.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-19842.pdf?1790599512","publication_date":"2026-09-29","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"handle marihuana for medical purposes, if applicable. \n See Schedules of Controlled Substances: <span class=\"match\">Rescheduling</span> of Food and Drug Administration Approved Products Containing <span class=\"match\">Marijuana</span> From Schedule I to Schedule III; Corresponding Change to Permit Requirements, \n 91 FR 22714, 22721 (2026) (adding paragraph (k) to 21 CFR 1301.13 “establish[ing] an expedited review process for entities holding state medical <span class=\"match\">marijuana</span> licenses who seek registration as a <span class=\"match\">marijuana</span> manufacturer”); \n see also id. \n at 22722 (adding paragraphs (g)(2)-(4) to 21 CFR 1308.13 placing"},{"title":"Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027","type":"Notice","abstract":"The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.","document_number":"2026-22843","html_url":"https://www.federalregister.gov/documents/2026/11/10/2026-22843/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22843.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22843.pdf?1794231909","publication_date":"2026-11-10","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Substances: <span class=\"match\">Rescheduling</span> of Food and Drug Administration Approved Products Containing <span class=\"match\">Marijuana</span> From Schedule I to Schedule III; Corresponding Change to Permit Requirements \n as a final rule which became effective on April 28, 2026.\n 15 \n \n This final rule places in schedule III drug products containing <span class=\"match\">marijuana</span> that have been approved by the FDA and drug products subject to a state medical <span class=\"match\">marijuana</span> license. The final rule assigned separate drug codes for schedule III <span class=\"match\">marijuana</span> in an FDA-approved product or subject to a state medical <span class=\"match\">marijuana</span> license"},{"title":"Schedules of Controlled Substances: Placement of Diphenidine in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places the substance diphenidine (1-(1,2- diphenylethyl)piperidine), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle diphenidine.","document_number":"2026-19231","html_url":"https://www.federalregister.gov/documents/2026/09/21/2026-19231/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-21/pdf/2026-19231.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-19231.pdf?1789735510","publication_date":"2026-09-21","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":" which, among other things, concluded that HHS' two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland, Attorney General, Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this final rule, there is no evidence that health care providers have widespread experience with medical use of diphenidine or that the use of diphenidine is recognized by entities that regulate the practice of medicine, so"},{"title":"Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I","type":"Rule","abstract":"With the issuance of this final order, the Administrator of the Drug Enforcement Administration is permanently placing 2-(4- methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (other names: N-pyrrolidino metonitazene or metonitazepyne) and 5- nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (other names: N-pyrrolidino protonitazene or protonitazepyne), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts are possible within the specific chemical designation, in schedule I under the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1961 Single Convention on Narcotic Drugs. This action imposes permanent regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research or conduct instructional activities with or possess), or handle N-pyrrolidino metonitazene and N-pyrrolidino protonitazene.","document_number":"2026-00362","html_url":"https://www.federalregister.gov/documents/2026/01/12/2026-00362/schedules-of-controlled-substances-placement-of-n-pyrrolidino-metonitazene-and-n-pyrrolidino","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-12/pdf/2026-00362.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00362.pdf?1767966316","publication_date":"2026-01-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this scheduling order, there is no evidence that health care providers have widespread experience with medical use of \n N \n -pyrrolidino metonitazene and \n N \n -pyrrolidino protonitazene or that the use of \n N \n -pyrrolidino"},{"title":"Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places substance 3-methoxyphencyclidine (1-(1-(3- methoxyphenyl)cyclohexyl)piperidine; 3-MeO-PCP), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 3-MeO-PCP.","document_number":"2026-05618","html_url":"https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-23/pdf/2026-05618.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-05618.pdf?1774010717","publication_date":"2026-03-23","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":" which, among other things, concluded that HHS' two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland, Attorney General, Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this final rule, there is no evidence that health care providers have widespread experience with medical use of 3-MeO-PCP or that the use of 3-MeO-PCP is recognized by entities that regulate the practice of medicine, so the"},{"title":"Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I","type":"Rule","abstract":"With the issuance of this final order, the Administrator of the Drug Enforcement Administration is permanently placing N-ethyl-2- (2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name: N-desethyl isotonitazene) and 2-(4-ethoxybenzyl)-5-nitro- 1-(2-(piperidin-1-yl)ethyl)-1H-benzimidazole (other names: N- piperidinyl etonitazene; etonitazepipne), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts are possible within the specific chemical designation, in schedule I under the Controlled Substances Act. This scheduling action discharges the United States' obligations under the Single Convention on Narcotic Drugs (1961). This action imposes permanent regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research or conduct instructional activities with or possess), or handle N-desethyl isotonitazene and N-piperidinyl etonitazene.","document_number":"2025-23717","html_url":"https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23717.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-23717.pdf?1766411118","publication_date":"2025-12-23","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this scheduling order, there is no evidence that health care providers have widespread experience with medical use of N-desethyl isotonitazene and N-piperidinyl etonitazene or that the use of N-desethyl isotonitazene and N-piperidinyl"},{"title":"Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places methyl 2-[[1-(4-fluorobutyl)indole-3- carbonyl]amino]-3,3-dimethyl-butanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA), N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1- yl)-1H-indazole-3-carboxamide (other name: ADB-4en-PINACA), ethyl 2- [[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (other names: 5F-EDMB-PICA; 5F-EDMB-2201), and methyl 2-(1-(4- fluorobenzyl)-1H-indole-3-carboxamido)-3-methyl butanoate (other name: MMB-FUBICA), including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4F-MDMB-BUTICA, ADB- 4en-PINACA, 5F-EDMB-PICA, or MMB-FUBICA.","document_number":"2026-08517","html_url":"https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08517.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08517.pdf?1777553120","publication_date":"2026-05-01","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this final rule, there is no evidence that health care providers have widespread experience with medical use of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, or MMB-FUBICA, or that the use of 4F-MDMB-BUTICA, ADB-4en-PINACA,"},{"title":"Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3- b]indol-1-one (other names: CUMYL-PEGACLONE; SGT-151), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle CUMYL-PEGACLONE.","document_number":"2026-09566","html_url":"https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-13/pdf/2026-09566.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-09566.pdf?1778589924","publication_date":"2026-05-13","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this final rule, there is no evidence that health care providers have widespread experience with medical use of CUMYL-PEGACLONE, or that the use of CUMYL-PEGACLONE is recognized by entities that regulate the practice of medicine"},{"title":"Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 4-fluoroamphetamine (4-FA; 1-(4- fluorophenyl)propan-2-amine; para-fluoroamphetamine), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4-fluoroamphetamine.","document_number":"2026-00633","html_url":"https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-15/pdf/2026-00633.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00633.pdf?1768398308","publication_date":"2026-01-15","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":" which, among other things, concluded that HHS' two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland, Attorney General, Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this final rule, there is no evidence that health care providers have widespread experience with medical use of 4-FA or that the use of 4-FA is recognized by entities that regulate the practice of medicine, so the two-part test"},{"title":"Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H- indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle MDMB-4en-PINACA.","document_number":"2026-08104","html_url":"https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-24/pdf/2026-08104.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08104.pdf?1776948327","publication_date":"2026-04-24","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this final rule, there is no evidence that health care providers have widespread experience with medical use of MDMB-4en-PINACA, or that the use of MDMB-4en-PINACA is recognized by entities that regulate the practice of medicine"},{"title":"Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I","type":"Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2- [(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.","document_number":"2026-12654","html_url":"https://www.federalregister.gov/documents/2026/06/24/2026-12654/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12654.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12654.pdf?1782218712","publication_date":"2026-06-24","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this notice of intent, there is no evidence that health care providers have widespread experience with medical use of \n O \n -DSMT or that the use of \n O \n -DSMT is recognized by entities that regulate the practice of medicine"},{"title":"Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 4-chloromethcathinone (4-CMC, 1-(4-chlorophenyl)- 2-(methylamino)propan-1-one), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4- chloromethcathinone.","document_number":"2025-20004","html_url":"https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-11-17/pdf/2025-20004.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-20004.pdf?1763127920","publication_date":"2025-11-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this final rule, there is no evidence that health care providers have widespread experience with medical use of 4-CMC or that the use of 4-CMC is recognized by entities that regulate the practice of medicine under either the"},{"title":"Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing methyl 2- [[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA), N-(1-amino-3,3-dimethyl-1- oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide (other name: ADB-4en-PINACA), ethyl 2-[[1-(5-fluoropentyl)indole-3- carbonyl]amino]-3,3-dimethyl-butanoate (other names: 5F-EDMB-PICA; 5F- EDMB-2201), and methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)- 3-methyl butanoate (other name: MMB-FUBICA), including their salts, isomers (including optical, positional, and geometric isomers), and salts of isomers, in schedule I of the Controlled Substances Act. 4F- MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA were temporarily scheduled in an order dated December 12, 2023. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, or MMB-FUBICA.","document_number":"2025-22963","html_url":"https://www.federalregister.gov/documents/2025/12/16/2025-22963/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-16/pdf/2025-22963.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-22963.pdf?1765806325","publication_date":"2025-12-16","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"opinion, which, among other things, concluded that HHS's two-part test would be sufficient to establish that a drug has a currently accepted medical use. Office of Legal Counsel, Memorandum for Merrick B. Garland Attorney General Re: Questions Related to the Potential <span class=\"match\">Rescheduling</span> of <span class=\"match\">Marijuana</span> at 3 (April 11, 2024). For purposes of this proposal, there is no evidence that health care providers have widespread experience with medical use of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, or MMB-FUBICA, or that the use of these substances is recognized by"}]}